| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Loxapine inhalation powder |
| Brand | Adasuve® |
| Indication | For the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. |
| Assessment Process | |
| Rapid review commissioned | 21/06/2016 |
| Rapid review completed | 28/07/2016 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
Not considered cost-effective due to non-submission of full pharmacoeonomic evaluation.